Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3616875, 10 pages
https://doi.org/10.1155/2017/3616875
Review Article

The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Meta-Analysis

1Department of Obstetrics & Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2Department of Obstetrics & Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
3Department of Obstetrics & Gynecology, Tufts University School of Medicine, Boston, MA, USA
4Department of Obstetrics and Gynecology, Hallym University Kangdong Sacred Heart Hospital, Seoul, Republic of Korea

Correspondence should be addressed to Banghyun Lee; rk.ro.myllah@eelnuyhgnab

Received 24 April 2017; Revised 24 June 2017; Accepted 23 November 2017; Published 17 December 2017

Academic Editor: Kotaro Kitaya

Copyright © 2017 Hee Joong Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Mesiano, Y. Wang, and E. R. Norwitz, “Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing?” Reproductive Sciences, vol. 18, no. 1, pp. 6–19, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. S. T. Nakajima, F. G. Nason, G. J. Badger, and M. Gibson, “Progesterone production in early pregnancy,” Fertility and Sterility, vol. 55, no. 3, pp. 516–521, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Z. Shi, Z. Y. Zhang, and L. Z. Zhuang, “Study on reproductive endocrinology of human placenta (III)–Hormonal regulation of progesterone production by trophoblast tissue of first trimester,” Science in China. Series B: Chemistry, Life Sciences and Earth Sciences, vol. 34, no. 9, pp. 1098–1104, 1991. View at Google Scholar
  4. M. A. Osmanaǧaoǧlu, I. Erdoǧan, S. Eminaǧaoǧlu et al., “The diagnostic value of β-human chorionic gonadotropin, progesterone, CA125 in the prediction of abortions,” Journal of Obstetrics & Gynaecology, vol. 30, no. 3, pp. 288–293, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. A. H. Al‐Sebai, C. R. Kingsland, M. Diver, L. Hipkin, and I. R. McFadyen, “The role of a single progesterone measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability,” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 102, no. 5, pp. 364–369, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. E. R. Norwitz and A. B. Caughey, “Progesterone supplementation and the prevention of preterm birth,” Reviews in Obstetrics and Gynecology, vol. 4, no. 2, pp. 60–72, 2011. View at Google Scholar
  7. C. Everett, “Incidence and outcome of bleeding before the 20th week of pregnancy: Prospective study from general practice,” British Medical Journal, vol. 315, no. 7099, pp. 32–34, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Carp, “A systematic review of dydrogesterone for the treatment of recurrent miscarriage,” Gynecological Endocrinology, vol. 31, no. 6, pp. 422–430, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. H. A. Wahabi, A. A. Fayed, S. A. Esmaeil, and R. A. Al Zeidan, “Progestogen for treating threatened miscarriag,” The Cochrane Database of Systematic Reviews, vol. 12, Article ID 005943, p. Cd005943, 2011. View at Google Scholar
  10. J. Kalinka and J. Szekeres-Bartho, “The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion,” American Journal of Reproductive Immunology, vol. 53, no. 4, pp. 166–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Alimohamadi, P. Javadian, M. H. Gharedaghi et al., “Progesterone and threatened abortion: A randomized clinical trial on endocervical cytokine concentrations,” Journal of Reproductive Immunology, vol. 98, no. 1-2, pp. 52–60, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Y. El-Zibdeh and L. T. Yousef, “Dydrogesterone support in threatened miscarriage,” Maturitas, vol. 65, no. 1, pp. S43–S46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Gerhard, B. Gwinner, W. Eggert-Kruse, and B. Runnebaum, “Double-blind controlled trial of progesterone substitution in threatened abortion,” Biological Research in Pregnancy and Perinatology, vol. 8, no. 1, pp. 26–34, 1987. View at Google Scholar · View at Scopus
  14. M. H. Omar, M. K. Mashita, P. S. Lim, and M. A. Jamil, “Dydrogesterone in threatened abortion: Pregnancy outcome,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 97, no. 5, pp. 421–425, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. R. U. Pandian, “Dydrogesterone in threatened miscarriage: A Malaysian experience,” Maturitas, vol. 65, no. 1, pp. S47–S50, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Palagiano, C. Bulletti, M. C. Pace, D. De Ziegler, E. Cicinelli, and A. Izzo, “Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy,” Annals of the New York Academy of Sciences, vol. 1034, pp. 200–210, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Yassaee, R. Shekarriz-Foumani, S. Afsari, and M. Fallahian, “The effect of progesterone suppositories on threatened abortion: A randomized clinical trial,” Journal of Reproduction and Infertility, vol. 15, no. 3, pp. 147–151, 2014. View at Google Scholar · View at Scopus
  18. E. H. Reerink, H. F. L. Schöler, P. Westerhof et al., “A new class of Hormonally active steroids,” Nature, vol. 186, no. 4719, pp. 168-169, 1960. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Czajkowski, J. Sienko, M. Mogilinski, M. Bros, R. Szczecina, and A. Czajkowska, “Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone,” Fertility and Sterility, vol. 87, no. 3, pp. 613–618, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Y. Y. Hui, S. J. Y. Siew, and T. C. Tan, “Biochemical and clinical outcomes following the use of micronised progesterone and dydrogesterone for threatened miscarriage-a randomised controlled trial [abstract EP13.55],” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 122, p. 276, 2015. View at Google Scholar
  21. G. Guyatt, A. D. Oxman, E. A. Akl et al., “GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings table,” Journal of Clinical Epidemiology, vol. 64, no. 4, pp. 383–394, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Lucovnik, R. J. Kuon, L. R. Chambliss et al., “Progestin treatment for the prevention of preterm birth,” Acta Obstetricia et Gynecologica Scandinavica, vol. 90, no. 10, pp. 1057–1069, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. G. C. Di Renzo, I. Giardina, G. Clerici, E. Brillo, and S. Gerli, “Progesterone in normal and pathological pregnancy,” Hormone Molecular Biology and Clinical Investigation, vol. 27, no. 1, pp. 35–48, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. P. J. Meis, M. Klebanoff, E. Thom et al., “Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate,” New England Journal of Medicine, vol. 348, no. 24, pp. 2379–2385, 2003. View at Google Scholar
  25. R. Romero, K. H. Nicolaides, A. Conde-Agudelo et al., “Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study,” Ultrasound in Obstetrics & Gynecology, vol. 48, no. 3, pp. 308–317, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Saccone, A. Khalifeh, A. Elimian et al., “Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials,” Ultrasound in Obstetrics & Gynecology, vol. 49, no. 3, pp. 315–321, 2017. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Rai, S. Rajaram, N. Goel, R. Ayalur Gopalakrishnan, R. Agarwal, and S. Mehta, “Oral micronized progesterone for prevention of preterm birth,” International Journal of Gynecology and Obstetrics, vol. 104, no. 1, pp. 40–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. W. P. Barbosa, L. R. Silva, P. A. Navarro, R. A. Ferriani, C. O. Nastri, and W. P. Martins, “Dydrogesterone vs progesterone for luteal-phase support: Systematic review and meta-analysis of randomized controlled trials,” Ultrasound in Obstetrics & Gynecology, vol. 48, no. 2, pp. 161–170, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. H. M. Fatemi, “The luteal phase after 3 decades of IVF: what do we know?” Reproductive BioMedicine Online, vol. 19, supplement 4, p. 4331, 2009. View at Google Scholar · View at Scopus